2021 Cooks' Tour Sponsors

Leadership

Jill and Mike Severino

Benefactor

Laura and Sami Elsaden
William Blair

Platinum

Goldberg Kohn Foundation

Sarah and Jonathan Graham

Nora and Ian Larkin

Lefkovitz Foundation

Jeanne and Ken McAtamney

Heather and Jim Pigott

Julie and Don Rocap

Gold

Andrea Goldman Design

Chalet

Kirkland & Ellis LLP

Katie and John Palmer

Winston & Strawn LLP

Media Partner

Sheridan Road

 

About

Stunning Homes. Life Saving Impact.

North Shore Cooks' Tour is a project of The Auxiliary of the Woman's Board of Rush University Medical Center in Chicago, IL. The Auxiliary and the Woman's Board* support the Medical Center's outstanding patient care, research and community outreach initiatives in the diverse communities that it serves.  

For the last 50 years, some of the most distinctive North Shore homes have generously opened their doors to benefit the work of Rush University Medical Center. 

Cooks' Tour is organized each September by the Auxiliary of the Woman's Board of Rush University Medical Center.  The event is much anticipated as the "perfect day out" for women throughout Chicago and the North Shore.  Guests will enjoy an intimate tour of each of the homes and a delicious boxed lunch.  In addition, guests can delight in the purchase of raffle tickets for coveted prizes, and various home related goods. 

The women of the board continue a proud tradition with their ongoing efforts to support the work of Rush University Medical Center.  All proceeds from the Cooks' Tour 2021 will support The Woman's Board Fund for Precision Oncology Research.

* For more information about the Woman's Board of Rush University Medical Center, visit: https://www.thewomansboard.org

Our Cause

The Woman's Board Fund for Precision Oncology Research

“In a person, we can only give one treatment at a time. With tumor organoids, we can divide the cells to test response to multiple drugs at the same time.“ Dr. Mia Levy, MD, PhD, director of Rush University Cancer Center

Tumor organoids are three-dimensional masses of cells artificially grown from a patient’s cancer cells and sometimes referred to as “mini tumors.” 

With additional research, this novel technology has the potential to be a game changer in cancer care, enabling scientists to study each patients’ unique case in the laboratory setting and evaluate the organoid’s response to several therapies — ultimately guiding oncologists’ selection of the most effective possible treatments. Support from The Woman’s Board will:

  • Contribute to the collection and storage of biospecimens and provide the seed funding needed to develop organoids

  • Provide the personnel resources to validate organoids and study how reliable they are at modeling each patients’ tumor

  • Allow researchers to conduct observational studies that answer the critical question: How effectively do organoids mimic the function of patients’ tumors when exposed to the same treatments? Does the drug response of the organoid match the tumor response in the person?

  • Enable scientists to gather preliminary data to apply for grant applications to sustain this leading-edge research

 
Cancer_Design_KH_2-2048x1366.jpg
0292_rush_bridge_002.jpg

The Power of Scale

The Woman’s Board Fund for Precision Oncology Research will scale and accelerate this research program, positioning Rush investigators among a small handful of research groups in the country and one of the most well-equipped to translate scientific findings into patient care. Funding will enable researchers to collect and store cancer tissues; develop three-dimensional tumor organoids; and lead translational research projects that improve outcomes for patients with lung, breast, ovarian, colorectal, and other cancers characterized by solid tumors. If a tumor organoid drug screen can predict a patient’s tumor response to treatment, potential applications include:

  • Future studies to evaluate the clinical utility of organoid drug screen in treatment decision making

  • Evaluate potential efficacy of novel drug treatments before clinical trials

  • Inform clinical trial designs for novel therapies

  • Enable studies to evaluate mechanisms of drug resistance

 

Rapid advancements in cancer research – particularly discoveries related to cancer’s genetic underpinnings — have empowered today’s oncologists with tools to evaluate each patient’s tumor at the molecular level and better predict how he or she will respond to available therapies. This approach is known as precision oncology, and although it is beginning to revolutionize cancer treatment, much more scientific study is needed to fully deliver on the promise of this research. At Rush, Dr. Levy has assembled a team of expert researchers including Jeffrey Borgia, PhD; Ashiq Masood, MD; and Casey Frankenberger, PhD, to advance precision oncology by developing and studying tumor organoids — a potential breakthrough in cancer research.

"Never doubt that a small group of thoughtful committed citizens can change the world: indeed, it's the only thing that ever has." - Margaret Mead

 

Contact The Cooks' Tour

Winnetka Auxiliary Board of RUMC

Attn:  Cooks' Tour

P.O. Box 142

Winnetka, IL 60093-0142

info@auxboardrumc.org